Forma Therapeutics Announces Appointment of New Executive Team Members
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer, and other rare hematologic diseases and cancers, today announced the appointment of Agustn Melin, M.D.
- Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer, and other rare hematologic diseases and cancers, today announced the appointment of Agustn Melin, M.D.
- In this capacity, he led the cross-functional research and development medical staff outside of the U.S. as well as Japan.
- Forma has a differentiated patient-centric culture and an amazing team.
- Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers.